Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
5.89 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Iovance Biotherapeutics, Inc. |
Symbool | IOVA |
Munteenheid | USD |
Prijs | 5.89 |
Beurswaarde | 1,795,160,090 |
Dividendpercentage | 0% |
52-weken bereik | 5.77 - 18.33 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Frederick G. Vogt Esq., J.D., Ph.D. |
Website | https://www.iovance.com |
An error occurred while fetching data.
Over Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)